Psychemedics Corp (PMD) 13.97 $PMD
Psychemedics Corporation Announces Record Revenues
PR Newswire - Mon Jul 28, 11:35AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 7, 2014 to be paid on August 18, 2014. This will be the Company's 72nd consecutive quarterly dividend.
Psychemedics Up 48.7% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Mar 27, 9:38AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 48.74% as of today's recent price of $17.67.
Psychemedics Shares Up 53.2% Since SmarTrend's Buy Recommendation (PMD)
Comtex SmarTrend(R) - Thu Mar 20, 9:11AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 53.20% as of today's recent price of $18.20.
Uptrend Call Working As Psychemedics Stock Rises 50.8% (PMD)
Comtex SmarTrend(R) - Wed Mar 12, 4:51PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 50.76% as of today's recent price of $17.91.
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Psychemedics Up 52.1% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Wed Mar 05, 11:04AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 52.10% as of today's recent price of $18.07.
Uptrend Call Working As Psychemedics Stock Rises 43.9% (PMD)
Comtex SmarTrend(R) - Wed Feb 26, 9:39AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 43.94% as of today's recent price of $17.10.
Shares of PMD Up 50.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 19, 9:10AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 50.84% as of today's recent price of $17.92.
Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018
M2 - Mon Feb 17, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/nx9bdf/drugs_of_abuse) has announced the addition of the "Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018" report to their offering. Globally, the drugs of abuse testing market is witnessing significant growth due to rising awareness of government and non-government organizations towards ill effects of illicit drugs and to control socio-economical losses associated with drug abuse. As a result, this market is expected to grow during 2013 - 2018. Some of the key driving factors for the drugs of abuse testing market are globally rising consumption of illicit drugs, adoption of drug of abuse (DOA) testing at organizational level, increased production of illicit drugs and their trade and increasing death rates/road accidents due to drug abuse. However, the market faces some restraints such as social concerns associated with illicit drugs testing, legalization of various drugs, and economic volatility and cost concerns. North America, including the US has the largest drugs of abuse testing market and also the fastest growing drugs of abuse testing market. Some of the fastest growing markets for drugs of abuse testing are US, UK, Japan, Germany and other European countries. According to UNODC report 2013, number of illicit drug users is estimated to increase from 167 million in 2009 to 315 million people in 2011. This corresponds to 3.6% to 6.9% of global adult population and cannabis, opioids and opiates were most commonly used illicit drugs. In various countries, including America and European countries, organizations are conducting drug screening test at various levels, such as pre-employment screening, random drug/alcohol screening, post incident drug/alcohol screening and abstinence monitoring. In many countries, government rules & regulations are also supporting the growth of drugs of abuse testing market, as they have outlined essential drug testing at workplace, such as in the US, Japan, Australia and the UK. This has emerged as a key driver for the market. Urine is the largest sample which is diagnosed in the drugs of abuse testing market. The other major samples for drugs of abuse testing are Saliva and Hair. Laboratory drug screening test requires a trained and skilled person to provide an accurate result and involves in-depth analysis. In laboratory screening test, usually the test is reconfirmed using gas chromatography/mass spectrometry or any other superior techniques to provide accurate results. On-site drug screening test gives results on the spot and it is generally preferred for those who take the drug test at home, workplace and educational institutions. The most common specimens used in on-site drug testing are urine, saliva and hair. Nowadays, commercially-available on-site screening test kits are usually designed for urine and saliva specimens only. Roche Diagnostics is the leading player in the global drugs of abuse testing market. Other major players of drugs of abuse testing market include Quest Diagnostics, LabCorp, Alere and Abbott Laboratories and others. Key Topics Covered - Preface - Executive Summary - Drugs of Abuse Testing Market - Industry Analysis - Porter's five force analysis - Global Drugs of Abuse Testing Market - Drugs of Abuse Testing Market - Testing Technology Analysis - Drugs of Abuse Testing Market - Sample Analysis - Single vs. Multiple Parameter Test - Drugs of Abuse Market - Regional Segment Analysis - Recent Developments - Company profiles Companies Mentioned - Abbott Laboratories - Alere - Bio-Rad Laboratories - LabCorp (Laboratory Corporation of America) - Psychemedics Corporation - Quest Diagnostic - Randox Laboratories - Roche Diagnostics - Sonic Healthcare - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/nx...s_of_abuse About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 13, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Shares of PMD Up 33.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 11, 4:56PM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 33.00% as of today's recent price of $15.80.
Psychemedics Corporation Announces 2013 Earnings Up 28% And Record Revenues
PR Newswire - Mon Feb 10, 11:03AM CST
Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 21, 2014 to be paid on March 7, 2014. This will be the Company's 70th consecutive quarterly dividend.
Psychemedics Has Returned 26.3% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Tue Feb 04, 11:05AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 26.26% as of today's recent price of $15.00.
32.7% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Tue Jan 28, 9:41AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 6 months, Psychemedics has returned 32.66% as of today's recent price of $15.76.
Uptrend Call Working As Psychemedics Stock Rises 28.3% (PMD)
Comtex SmarTrend(R) - Fri Jan 10, 4:41PM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ MD) on July 24th, 2013 at $11.88. In approximately 6 months, Psychemedics has returned 28.28% as of today's recent price of $15.24.
Psychemedics Corporation Announces Record Revenues
PR Newswire - Mon Jul 28, 11:35AM CDT
Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 7, 2014 to be paid on August 18, 2014. This will be the Company's 72nd consecutive quarterly dividend.
Psychemedics Up 48.7% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Thu Mar 27, 9:38AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 48.74% as of today's recent price of $17.67. Psychemedics Shares Up 53.2% Since SmarTrend's Buy Recommendation (PMD)
Comtex SmarTrend(R) - Thu Mar 20, 9:11AM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 53.20% as of today's recent price of $18.20. Uptrend Call Working As Psychemedics Stock Rises 50.8% (PMD)
Comtex SmarTrend(R) - Wed Mar 12, 4:51PM CDT
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 8 months, Psychemedics has returned 50.76% as of today's recent price of $17.91. 2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Psychemedics Up 52.1% Since SmarTrend Uptrend Call (PMD)
Comtex SmarTrend(R) - Wed Mar 05, 11:04AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 52.10% as of today's recent price of $18.07. Uptrend Call Working As Psychemedics Stock Rises 43.9% (PMD)
Comtex SmarTrend(R) - Wed Feb 26, 9:39AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 43.94% as of today's recent price of $17.10. Shares of PMD Up 50.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 19, 9:10AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 50.84% as of today's recent price of $17.92. Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018
M2 - Mon Feb 17, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/nx9bdf/drugs_of_abuse) has announced the addition of the "Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018" report to their offering. Globally, the drugs of abuse testing market is witnessing significant growth due to rising awareness of government and non-government organizations towards ill effects of illicit drugs and to control socio-economical losses associated with drug abuse. As a result, this market is expected to grow during 2013 - 2018. Some of the key driving factors for the drugs of abuse testing market are globally rising consumption of illicit drugs, adoption of drug of abuse (DOA) testing at organizational level, increased production of illicit drugs and their trade and increasing death rates/road accidents due to drug abuse. However, the market faces some restraints such as social concerns associated with illicit drugs testing, legalization of various drugs, and economic volatility and cost concerns. North America, including the US has the largest drugs of abuse testing market and also the fastest growing drugs of abuse testing market. Some of the fastest growing markets for drugs of abuse testing are US, UK, Japan, Germany and other European countries. According to UNODC report 2013, number of illicit drug users is estimated to increase from 167 million in 2009 to 315 million people in 2011. This corresponds to 3.6% to 6.9% of global adult population and cannabis, opioids and opiates were most commonly used illicit drugs. In various countries, including America and European countries, organizations are conducting drug screening test at various levels, such as pre-employment screening, random drug/alcohol screening, post incident drug/alcohol screening and abstinence monitoring. In many countries, government rules & regulations are also supporting the growth of drugs of abuse testing market, as they have outlined essential drug testing at workplace, such as in the US, Japan, Australia and the UK. This has emerged as a key driver for the market. Urine is the largest sample which is diagnosed in the drugs of abuse testing market. The other major samples for drugs of abuse testing are Saliva and Hair. Laboratory drug screening test requires a trained and skilled person to provide an accurate result and involves in-depth analysis. In laboratory screening test, usually the test is reconfirmed using gas chromatography/mass spectrometry or any other superior techniques to provide accurate results. On-site drug screening test gives results on the spot and it is generally preferred for those who take the drug test at home, workplace and educational institutions. The most common specimens used in on-site drug testing are urine, saliva and hair. Nowadays, commercially-available on-site screening test kits are usually designed for urine and saliva specimens only. Roche Diagnostics is the leading player in the global drugs of abuse testing market. Other major players of drugs of abuse testing market include Quest Diagnostics, LabCorp, Alere and Abbott Laboratories and others. Key Topics Covered - Preface - Executive Summary - Drugs of Abuse Testing Market - Industry Analysis - Porter's five force analysis - Global Drugs of Abuse Testing Market - Drugs of Abuse Testing Market - Testing Technology Analysis - Drugs of Abuse Testing Market - Sample Analysis - Single vs. Multiple Parameter Test - Drugs of Abuse Market - Regional Segment Analysis - Recent Developments - Company profiles Companies Mentioned - Abbott Laboratories - Alere - Bio-Rad Laboratories - LabCorp (Laboratory Corporation of America) - Psychemedics Corporation - Quest Diagnostic - Randox Laboratories - Roche Diagnostics - Sonic Healthcare - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/nx...s_of_abuse About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 13, 12:25PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Shares of PMD Up 33.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 11, 4:56PM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 33.00% as of today's recent price of $15.80. Psychemedics Corporation Announces 2013 Earnings Up 28% And Record Revenues
PR Newswire - Mon Feb 10, 11:03AM CST
Psychemedics Corporation (NASDAQ: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2013. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of February 21, 2014 to be paid on March 7, 2014. This will be the Company's 70th consecutive quarterly dividend.
Psychemedics Has Returned 26.3% Since SmarTrend Recommendation (PMD)
Comtex SmarTrend(R) - Tue Feb 04, 11:05AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 7 months, Psychemedics has returned 26.26% as of today's recent price of $15.00. 32.7% Return Seen to Date on SmarTrend Psychemedics Call (PMD)
Comtex SmarTrend(R) - Tue Jan 28, 9:41AM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 6 months, Psychemedics has returned 32.66% as of today's recent price of $15.76. Uptrend Call Working As Psychemedics Stock Rises 28.3% (PMD)
Comtex SmarTrend(R) - Fri Jan 10, 4:41PM CST
SmarTrend identified an Uptrend for Psychemedics (NASDAQ
MD) on July 24th, 2013 at $11.88. In approximately 6 months, Psychemedics has returned 28.28% as of today's recent price of $15.24. 
